David Reininger, MD
Internal Medicine · Katy, TXNPI 1306846043
Payments from drug & device makers
Across 251 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$641
- AstraZeneca$406
- Johnson & Johnson$359
- GSK$308
- Acadia Pharmaceuticals Inc$298
- Pfizer$154
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,816100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $641 |
| AstraZeneca | 25 | $406 |
| Johnson & Johnson(2 entities) | 29 | $359 |
| GSK | 23 | $308 |
| Acadia Pharmaceuticals Inc | 8 | $298 |
| Pfizer | 11 | $154 |
| Otsuka America Pharmaceutical, Inc. | 7 | $151 |
| Novartis | 9 | $143 |
| Sanofi-aventis U.S. LLC | 11 | $141 |
| Astellas Pharma US Inc | 7 | $124 |
| Boehringer Ingelheim | 8 | $110 |
| Merck | 9 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $98 |
| Mannkind Corporation | 7 | $97 |
| Sunovion Pharmaceuticals Inc. | 5 | $83 |
| Mylan Specialty L.p. | 3 | $80 |
| Abbott | 4 | $77 |
| AbbVie | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $58 |
| Amgen | 4 | $52 |
| Urovant Sciences Inc | 1 | $44 |
| Bayer | 2 | $27 |
| Lilly USA, LLC | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| CMP Pharma, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$120
How this compares
$3,824 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $59,194 |
| NuplazidPimavanserin Tartrate | 22 | $53,550 |
| OzempicSemaglutide | 18 | $18,677 |
| MyrbetriqMirabegron | 63 | $13,839 |
| LinzessLinaclotide | 32 | $13,763 |
| Daptomycin | 15 | $11,646 |
| LumiganBimatoprost | 37 | $10,085 |
| FarxigaDapagliflozin Propanediol | 32 | $9,239 |
| Memantine Hcl | 191 | $7,734 |
| JanuviaSitagliptin Phosphate | 20 | $6,967 |
| TradjentaLinagliptin | 24 | $6,655 |
| Divalproex Sodium | 143 | $6,174 |
| TrintellixVortioxetine Hydrobromide | 24 | $5,882 |
| JardianceEmpagliflozin | 14 | $4,981 |
| Levothyroxine Sodium | 491 | $4,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $59,194206 claims |
| Acadia Pharmaceuticals IncNuplazid | $298 | $53,55022 claims |
| AbbVieLinzess, Lumigan, Combigan | $63 | $27,39585 claims |
| Novo NordiskOzempic | $641 | $18,67718 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $13,83963 claims |
| AstraZenecaFarxiga, Brilinta | $406 | $11,95344 claims |
| Boehringer IngelheimTradjenta, Jardiance | $110 | $11,63638 claims |
| MerckJanuvia | $110 | $6,96720 claims |
| GSKArnuity Ellipta | $308 | $2,62712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Katy
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.